Drug Trial Radar · NCT06038279
Trial of INI-2004 in Healthy Volunteers and Participants With Allergic Rhinitis.
Last checked: Nov 19, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
68
Actual
Start
Jul 4, 2023
Primary completion
Sep 5, 2024
Study completion Sep 5, 2024
Sponsor
- Lead sponsor
- Inimmune CorporationIndustry
- Sponsor type
- Industry
- Collaborators
- Avance Clinical Pty Ltd.
- First posted
- Sep 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase I/Ib, randomised, double-blind, placebo-controlled study of INI-2004, administered as single or multiple doses. This study will be conducted in two parts: Phase I single ascending dose (SAD) and Phase Ib multiple ascending dose (MAD).
Conditions
- Allergic Rhinitis Due to Weed Pollen
- Allergic Rhinitis
Interventions
INI-2004Drug
INI-2004 (a toll-like receptor \[TLR\]4 agonist) liposomal formulation. INI-2004 is an intranasal (IN) TLR4 agonist that is targeted to prevent AR symptoms in subjects with seasonal AR.
PlaceboDrug
The Placebo for INI-2004 is a clear, colorless solution free of particles supplied in 10 mL glass vials with a 10 mL fill.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence, severity and relationship of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and TEAEs leading to discontinuation of study treatment after a single ascending Dose (SAD)Time frame: Baseline, Day 1 then daily through to Day 7 End of Study Visit
- Incidence, severity and relationship of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and TEAEs leading to discontinuation of study treatment after multiple ascending doses (MAD)Time frame: Baseline = Day 0, Day 14, 21, 28, 35 through to Day 58 End of Study Visit
- Number of Participants with a Change from baseline in Vital signs measurements after a single ascending Dose (SAD)Time frame: Baseline, Day 1 through to Day 7 End of Study Visit
- Number of Participants with a Change from baseline in Vital signs measurements after multiple ascending doses (MAD)Time frame: Baseline = Day 0 through to Day 58 End of Study Visit
- Change from baseline in 12-lead electrocardiogram parameters after a single ascending Dose (SAD)Time frame: Baseline, Day 1 through to Day 7 End of Study Visit
- Change from baseline in 12-lead electrocardiogram parameters after multiple ascending doses (MAD)Time frame: Baseline = Day 0 through to Day 58 End of Study Visit
- Number of Participants with a Change from baseline in Clinical laboratory results after a single ascending Dose (SAD)Time frame: Baseline, Day 2 through to Day 7 End of Study Visit
- Number of Participants with a Change from baseline in Clinical laboratory results after a single ascending Dose (SAD)Time frame: Baseline, Day 2 through to Day 7 End of Study Visit
- Number of Participants with a Change from baseline in Clinical laboratory results after a single ascending Dose (SAD)Time frame: Baseline, Day 2 through to Day 7 End of Study Visit
- Number of Participants with a Change from baseline in Clinical laboratory results after multiple ascending doses (MAD)Time frame: Baseline = Day 0, Day 14 and Day 58 End of Study Visit
- Number of Participants with a Change from baseline in Clinical laboratory results after multiple ascending doses (MAD)Time frame: Baseline = Day 0, Day 14 and Day 58 End of Study Visit
- Number of Participants with a Change from baseline in Clinical laboratory results after multiple ascending doses (MAD)Time frame: Baseline = Day 0, Day 14 and Day 58 End of Study Visit
- Change from baseline in Nasal symptoms after a single ascending Dose (SAD)Time frame: Baseline, Day 1 through to Day 7 End of Study Visit
- Change from baseline in Nasal symptoms after multiple ascending doses (MAD)Time frame: Baseline = Day 0 through to Day 58 End of Study Visit
- Change from baseline in Nasal irritancy after a single ascending Dose (SAD)Time frame: Baseline, Day 1 through to Day 7 End of Study Visit
- Change from baseline in Nasal irritancy after multiple ascending doses (MAD)Time frame: Baseline = Day 0 through to Day 58 End of Study Visit
- Change from baseline in Spirometry after a single ascending Dose (SAD)Time frame: Baseline, Day 1 through to Day 7 End of Study Visit
- Change from baseline in Spirometry after a single ascending Dose (SAD)Time frame: Baseline, Day 1 through to Day 7 End of Study Visit
- Change from baseline in Spirometry after a single ascending Dose (SAD)Time frame: Baseline, Day 1 through to Day 7 End of Study Visit
- Change from baseline in Spirometry after a single ascending Dose (SAD)Time frame: Baseline, Day 1 through to Day 7 End of Study Visit
- Change from baseline in Spirometry after a single ascending Dose (SAD)Time frame: Baseline, Day 1 through to Day 7 End of Study Visit
- Change from baseline in Spirometry after multiple ascending doses (MAD)Time frame: Baseline = Day 0 through to Day 58 End of Study Visit
- Change from baseline in Spirometry after multiple ascending doses (MAD)Time frame: Baseline = Day 0 through to Day 58 End of Study Visit
- Change from baseline in Spirometry after multiple ascending doses (MAD)Time frame: Baseline = Day 0 through to Day 58 End of Study Visit
- Change from baseline in Spirometry after multiple ascending doses (MAD)Time frame: Baseline = Day 0 through to Day 58 End of Study Visit
- Change from baseline in Spirometry after multiple ascending doses (MAD)Time frame: Baseline = Day 0 through to Day 58 End of Study Visit
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network Pty Ltd
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.